Results 241 to 250 of about 144,091 (315)

Enhancement of immune checkpoint inhibitor efficacy by DHX58+ SELL+ T cells in advanced gastric cancer

VIEW, EarlyView.
We created a coculture system using patient‐derived organoids (PDOs) and tumor‐infiltrating lymphocytes (TILs) that mimics important interactions between PDOs and TILs in the presence of various ICIs. Our findings reveal that CD62L+ T cells, activated by CD44+ cancer stem cells (CSCs), facilitate tumor regression in samples sensitive to ICIs, which is ...
Jie Chen, Youdong Liu, Hongda Pan, Tianyi Cai, Mingde Zang, Xiaowen Liu, Ziwen Long, Xin Fan, Jun Lu, Fenglin Liu   +9 more
wiley   +1 more source

Plasma Proteomics Analysis Identifying IGFBP2 as a Potential Diagnostic Biomarker for Laryngeal Squamous Cell Carcinoma

World Journal of Otorhinolaryngology - Head and Neck Surgery, EarlyView.
ABSTRACT Objective Currently, there are no blood biomarkers available for the early diagnosis of laryngeal squamous cell carcinoma (LSCC). The objective of this study was to search for potential plasma biomarkers for the diagnosis of LSCC. Methods Plasma samples were taken from patients with LSCC and healthy controls for proteomic analysis.
Shuang Teng, Ling‐Mei Qu, Jun‐Jie Liu, Yu‐Shan Li, Zi‐Qi Chen, Shuo Liu, Zhao‐Nan Xu, Meng Jin, Qiu‐Ying Li, Qin Wu, Hong‐Tian Yi, Xian‐Ji Shen, Bing‐Rui Yan, Ya‐Nan Sun   +13 more
wiley   +1 more source

Advances in cancer immunotherapy: adoptive cell therapy and immune cell engagers in solid tumours. [PDF]

Br J Cancer
Panasci J, Park CL, Tran B, Siu LL.
europepmc   +1 more source

Towards the Development of a Conceptual Framework of the Determinants of Pre‐eclampsia: A Hierarchical Systematic Review of Biomarkers

BJOG: An International Journal of Obstetrics &Gynaecology, EarlyView.
ABSTRACT Background Pre‐eclampsia is a leading cause of maternal and perinatal morbidity and mortality. There are several determinants of individual pregnant women's risk of developing pre‐eclampsia, including biomarkers and ultrasound markers. Objective A conceptual framework to collate and summarise the extensive body of literature on biomarkers ...
Terteel Elawad, Hiten D. Mistry, Mai‐Lei Woo Kinshella, Marianne Vidler, Marie‐Laure Volvert, Helen Elwell, Veronique Filippi, Kelly Pickerill, Rachel Craik, Joel Singer, Rosemary Townsend, Hannah Blencowe, Eleni Z. Tsigas, Jeffrey N. Bone, Peter von Dadelszen, Laura A. Magee, the PRECISE Network, Umberto D’Alessandro, Anna Roca, Hawanatu Jah, Andrew Prentice, Melisa Martinez‐Alvarez, Brahima Diallo, Abdul Sesay, Sambou Suso, Baboucarr Njie, Fatima Touray, Yahaya Idris, Fatoumata Kongira, Modou F. S. Ndure, Lawrence Gibba, Abdoulie Bah, Yorro Bah, Marleen Temmerman, Angela Koech, Patricia Okiro, Geoffrey Omuse, Grace Mwashigadi, Mary Goretti Amondi, Consolata Juma, Joseph Mutunga, Moses Mukhanya, Robin Okello, Onesmus Wanje, Isaac Mwaniki, Marvin Ochieng, Emily Mwadime, Esperança Sevene, Corssino Tchavana, Salesio Macuacua, Anifa Vala, Helena Boene, Lazaro Quimice, Sonia Maculuve, Inacio Mandomando, Peter von Dadelszen, Laura A. Magee, Rachel Craik, Marie‐Laure Volvert, Hiten Mistry, Thomas Mendy, Donna Russell, Prestige Tatenda Makanga, Liberty Makacha, Reason Mlambo, Lucilla Poston, Rachel Tribe, Sophie Moore, Tatiana Salisbury, Aris Papageorghiou, Alison Noble, Rachel Craik, Hannah Blencowe, Veronique Filippi, Joy Lawn, Matt Silver, Joseph Akuze, Ursula Gazeley, Judith Cartwright, Guy Whitley, Sanjeev Krishna, Marianne Vidler, Jing Li, Jeff Bone, Mai‐Lei Woo Kinshella, Domena Tu, Ash Sandhu, Kelly Pickerill, Carla Carillho, Benjamin Barratt   +89 more
wiley   +1 more source

HLA-DR risk variants in rheumatoid arthritis: what we know and still do not know. [PDF]

RMD Open
Yap CF, Viatte S.
europepmc   +1 more source

Myeloablative Busulfan, Fludarabine and Melphalan Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation in Childhood Myeloid Malignancy

Asia-Pacific Journal of Clinical Oncology, EarlyView.
We report our single‐center experience of transplant outcomes with a busulfan, fludarabine and melphalan‐based conditioning regimen for children < 18 years of age. The regimen was shown to be well tolerated and effective for heavily pretreated children with high‐risk myeloid malignancies prior to allogeneic hematopoietic stem cell transplant.
Mayank Dhamija, Fiona Kerr, Hazel Gough, Johnathan Soggee, Laurence C. Cheung, Rishi S. Kotecha, Shanti Ramachandran   +6 more
wiley   +1 more source

The impact of antigen presentation on BBB disruption and neuroinflammation. [PDF]

Physiology (Bethesda)
Maynes MA, Johnson AJ.
europepmc   +1 more source

Epstein‐Barr virus as a driver of lupus: Rethinking triggers in autoimmunity

Rheumatology &Autoimmunity, EarlyView.
Jiekai Tan, Fanlei Hu, Chuanhui Xu
wiley   +1 more source

Type I and II Interferons Drive Abacavir Hypersensitivity via Treg Suppression and T‐Cell Enhancement in Immunocompetent HLA‐Transgenic Mice

Allergy, EarlyView.
Upregulated HLA‐B*57:01 expression in Tg/KO mice amplifies abacavir‐specific CD8+ T‐cell activation, driven by enhanced antigen presentation. Abacavir treatment induces robust pDC expansion and IFN‐α production, which selectively suppresses memory Treg populations.
SuJin Hwang, Telly Sepahpour, Stephanie Kortchak, Kirthiram Krishnaveni Sivakumar, Spyros Karaiskos, Ngoc Pham, Yura Jang, Montserrat Puig, Michael Norcross   +8 more
wiley   +1 more source

Rapid identification of antigen-specific TCRs for cancer immunotherapy. [PDF]

Biophys Rep
Jiang M, Wang W, Tan S.
europepmc   +1 more source